Albert Bourla - Pfizer President
| PFE Stock | EUR 23.60 0.03 0.13% |
President
Mr. Albert Bourla is Chief Executive Officer, Director of Pfizer Inc. He was served as Chief Operating Officer of Pfizer from January 2018 to December 2018 Group President, Pfizer Innovative Health from June 2016 until December 2017 Group President, Global Innovative Pharma Business of Pfizer from February 2016 until June 2016 . President and General Manager of Established Products Business Unit of Pfizer from 2010 until 2013. Area President Europe, Africa, Asia and Pacific of Pfizer Animal Health from 2009 until 2010. Area President Europe, Africa and Middle East of Pfizer Animal Health from 2005 until 2009. Since joining Pfizer in 1993, Dr. Bourla has served in various leadership positions with increasing responsibility within Pfizers former Animal Health and global commercial organizations.Board member of Pharmaceutical Research and Manufacturers of America . Board member of the Pfizer Foundation, which promotes access to quality healthcare. Member of the Board of the Partnership for New York City and Catalyst, a global nonprofit organization accelerating progress for the advancement of women in leadership. since 2020.
| Age | 57 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
| Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
| Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Lead Independent Director | ||
| Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
| Susan DesmondHellmann, Director | ||
| Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
| Gordon Loh, Senior Vice President Corporate Audit | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
| Susan Hockfield, Independent Director | ||
| Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
| Dan Littman, Independent Director | ||
| James Kilts, Independent Director | ||
| James Quincey, Independent Director | ||
| Joseph Echevarria, Independent Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Angela Hwang, Group President, Pfizer Biopharmaceuticals Group | ||
| Scott Gottlieb, Independent Director | ||
| Ronald Blaylock, Independent Director |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 276.06 B | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 2.90 X | |||
| Revenue | 100.33 B | |||
| EBITDA | 39.58 B | |||
| Net Income | 31.37 B | |||
| Total Debt | 34.76 B | |||
| Cash Flow From Operations | 32.58 B | |||
| Price To Earnings To Growth | 1.17 X | |||
| Number Of Employees | 39 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.